🌟 New Insights on ADHD! Our latest report dives deep into the ADHD market, valued at $11.9 billion in 2022 across the US, France, Germany, Italy, Spain, the UK, and Japan 📊. Despite a projected decline, ADHD remains a clinically heterogeneous disorder with significant unmet needs 🌍. Explore the comprehensive assessment of ADHD epidemiology, clinical trials, and future forecasts until 2032 📅. https://lnkd.in/gfgwp9Wq #ADHD #Healthcare #MarketReport #NeurodevelopmentalDisorders #GlobalHealth
GlobalData Healthcare
Information Services
Predict the future to transform your business in the healthcare, medical devices & pharma industries.
About us
GlobalData is a one-stop solution for actionable insight into the pharmaceutical and medical device sectors. Together with the best team of researchers, analysts, epidemiologists and consultants, and an unmatched suite of proprietary databases, we provide high-quality, accurate and transparent insight that can help you achieve growth and increase business value. Our valuable research and consulting solutions ensure you stay at the forefront of the industry by integrating accurate market forecasts and healthcare analytics on the latest trends and developments. Among other benefits, our informed healthcare industry perspectives have assisted businesses based across the pharmaceuticals, biotechnology and medical equipment markets in making strategic decisions that have increased the value of their products and services. Among other benefits, our informed industry perspectives help clients understand how to generate the maximum return from their key markets, identify opportunities from emerging trends, and devise strategies for growth with confidence.
- Website
-
https://www.globaldata.com/
External link for GlobalData Healthcare
- Industry
- Information Services
- Company size
- 1,001-5,000 employees
- Headquarters
- London
- Type
- Public Company
- Founded
- 2010
- Specialties
- Research and Consulting, Strategic Analysis, Competitive Benchmarking, Market Forecasting, Medical, Pharmaceutical, and Data Analysis
Locations
-
Primary
John Carpenter Street
London, GB
Employees at GlobalData Healthcare
-
Alan Raider
Life-science industry sales and BD professional
-
Kate Sandman
Enabling Decisions via Data, Analytic Tools and Critical Insights on BioPharma
-
Ronald Cohen
Vice President; Strategic Partner to the Pharmaceutical Industry.
-
Valentina Gburcik
Senior Director at GlobalData Healthcare
Updates
-
🌟 Embracing the future of healthcare with AI-powered diagnostics! The shift towards precision medicine is here, and it's transforming patient safety. AI diagnostic tools analyze biological and clinical data to create personalized healthcare plans. Elia Garcia from GlobalData highlights the integration of AI into electronic medical records. This innovation offers clinicians easy access to diagnostic insights and patient data. 📊 The FDA's approval of Prenosis’ Sepsis ImmunoScore is a game-changer for patient safety in hospitals. This AI tool enhances clinical workflow efficiency and collaborative decision-making. https://lnkd.in/g5WSsry3 #AIinHealthcare #PrecisionMedicine #PatientSafety #DigitalHealth
AI-powered diagnostics in digital healthcare transforming patient safety, says GlobalData
globaldata.com
-
📊 Looking for extensive coverage of the radiosurgery systems market? Our latest market report has got you covered! 🌟 Dive into major pipeline products, complete with descriptions, licensing, collaborations, and developmental activities. 📝 Discover the impact of COVID-19 and stay ahead with key clinical trial data on ongoing trials. 🧬 Don't miss out on insights from top players and their projects! 🔗 Ready to explore the future of radiosurgery systems? Check out the report now! https://lnkd.in/gsDCgM_Y #Radiosurgery #HealthcareInnovation #MedicalTechnology #ClinicalTrials #COVID19Impact #MarketInsights #FutureOfHealthcare
Radiosurgery Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
globaldata.com
-
1 curated daily email 📬 8 #healthcare news stories 💡 100s of business opportunities 🌍 Subscribe now to get your #DECODED newsletter 👉 https://lnkd.in/eD2Qq9m4
-
-
🚀 Exciting Insights into GLP-1R Agonists for Type 2 Diabetes and Obesity! Our latest report provides a comprehensive overview of GLP-1R agonists, covering epidemiology, symptoms, diagnosis, and disease management. 📊 It includes annualized market revenue, cost of therapy, and treatment usage patterns forecasted from 2023 to 2033. 🗓️ Dive into strategic competitor assessments, market characterization, and unmet needs. 🔍 Explore emerging trends and dual/triple mechanisms of action in development for type 2 diabetes and obesity. 🌐 Don't miss the insightful review of key industry drivers, restraints, and challenges! 📈 https://lnkd.in/gbTyhs-c #DiabetesCare #ObesityTreatment #GLP1R #HealthcareInnovation #MarketAnalysis #EmergingTrends #ClinicalTrials
Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in Major Markets, Disease Overview and Drug Forecast to 2033
globaldata.com
-
June marks National Congenital Cytomegalovirus Awareness Month, raising awareness about CMV, a common virus with potentially severe consequences for newborns, including hearing loss and cerebral palsy. 🏥 🧪 CMV testing, especially for pregnant women, is crucial. GlobalData emphasizes the lack of routine CMV screening in major health markets like the US and UK, potentially delaying diagnosis and treatment. 🩺 💡 Selena Yu, Senior Medical Analyst at GlobalData, highlights that despite 60 CMV tests available, many asymptomatic pregnancies remain unscreened. Let's work towards better awareness and testing! https://lnkd.in/gKz75hDn #CMVAwareness #Healthcare #Pregnancy #NewbornHealth #CMVTesting #GlobalData #PublicHealth
GlobalData highlights importance of CMV tests during National Congenital Cytomegalovirus Awareness Month - GlobalData
globaldata.com
-
🔍 Dive into the latest insights on the Point of Care (POC) Analyzers Market! Discover how COVID-19 has reshaped this vital sector and strategize your next moves with actionable data. 📊 Explore pipeline products and technologies to streamline your in-licensing and out-licensing strategies. 🌐 Gain a competitive edge by understanding the POC analyzer's market growth trends. 🚀 https://lnkd.in/gQxjz5CW 👉 How do you envision the future of POC analyzers impacting healthcare delivery? Drop your thoughts below! #POCAnalyzers #HealthcareTechnology #COVID19Impact #MarketInsights #BusinessStrategy #HealthcareInnovation #MedicalDevices #GlobalHealth #HealthcareTrends
Point of Care (POC) Analyzers Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
globaldata.com
-
📣 We're excited to share the latest #insights from our report, ‘Obesity’s Impact on California's Economy and Labor Force'. This study revealed the staggering toll that #obesity and #overweight had on California's economy – $89.5 billion in 2022, equivalent to 2.5% of the state’s gross domestic product. Considering the analysis, GlobalData has recommended actionable steps for employers: - Offer insurance coverage and wellness programs for obesity care at parity with other chronic diseases. - Implement wellness programs. - Foster a culture of support and inclusion that recognizes and accommodates the needs of employees with obesity. - Provide education and resources to employees to educate them about the health risks associated with obesity as well as strategies for obesity care and weight management. 🔎 Our report serves as a wake-up call to address the #obesity crisis head-on, with employers being crucial stakeholders in efforts to foster a healthier and more prosperous future for employees and their families. The study was supported by Eli Lilly and Company. 📖 Read our detailed insights here: 👉 https://lnkd.in/gFrPrH9s 👉 https://lnkd.in/g2cjbGxY 👉 https://lnkd.in/gvvPAB2Q #healthcare #obesityimpact #overweight #US #casestudy #globaldata #elililly
-
Want access to our data for free? 👀 Subscribe to your #DECODED #Healthcare newsletter now 👉 https://lnkd.in/eYNJ8JKe
-
-
🌟 Exciting news in the world of vaccines! Moderna’s mRESVIA has just received FDA approval for use in adults aged 60+! This is the first mRNA vaccine approved for a disease other than COVID-19, marking a huge milestone for mRNA technology. Anaelle Tannen, Infectious Disease Analyst at GlobalData, highlights that mRESVIA is set to be the third RSV vaccine in the US market, following GSK’s Arexvy and Pfizer’s Abrysvo. However, mRESVIA stands out as the first mRNA vaccine to protect against RSV, showcasing the rapid design and production capabilities of mRNA technology. https://lnkd.in/gVb4yxNx What other diseases do you think mRNA technology will tackle next? Share your thoughts below! ⬇️ #Moderna #mRNA #VaccineInnovation #Healthcare #Biotechnology #RSV #FDAApproval #GlobalData
Moderna’s mRESVIA FDA approval paves way for mRNA vaccines across multiple indications, says GlobalData - GlobalData
globaldata.com